JP2000506853A - プロサポジン由来のペプチドを使用する神経障害痛の軽減方法 - Google Patents
プロサポジン由来のペプチドを使用する神経障害痛の軽減方法Info
- Publication number
- JP2000506853A JP2000506853A JP9532050A JP53205097A JP2000506853A JP 2000506853 A JP2000506853 A JP 2000506853A JP 9532050 A JP9532050 A JP 9532050A JP 53205097 A JP53205097 A JP 53205097A JP 2000506853 A JP2000506853 A JP 2000506853A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- neuropathic pain
- active fragment
- prosapodin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約14から約50のアミノ酸を有し、配列番号2に示す配列を含有する、プロ サポジン由来のペプチド。 2.ペプチドが配列番号2に示す配列を有する、請求項1のペプチド。 3.製薬上許容される担体中に請求項1または2のペプチドを含む、神経組織 中の神経または脱髄疾患の治療用の医薬組成物。 4.放出制御製剤の請求項3の組成物。 5.リポソーム形態の請求項3の組成物。 6.凍結乾燥形態の請求項3の組成物。 7.単位用量形態の請求項3の組成物。 8.被検者に有効量のプロサポジンの活性断片を投与することを含む、被検者 の神経障害痛を軽減する方法。 9.活性断片が配列番号1および配列番号2からなる群より選択されるアミノ 酸配列を有する、請求項8の方法。 10.神経障害痛が末梢神経疾患を原因とするものである、請求項8の方法。 11.末梢神経疾患が神経腫;神経圧迫;神経挫滅、神経伸張および不完全神経 離断;単発神経障害および多発神経障害からなる群より選択される、請求項10の 方法。 12.神経障害痛が脊髄後根神経節、脊髄、脳幹、視床または皮質の疾患からな る群より選択される疾患を原因とするものである、請求項8の方法。 13.投与が静脈内、筋肉内、皮内、皮下、頭蓋内、脳脊髄内、局所、経口、経 皮、経粘膜および経鼻からなる群より選択される、請求項8の方法。 14.被検者に有効量のプロサポジンの活性断片を投与することを含む、被検者 の神経障害痛を予防する方法。 15.活性断片が配列番号1および配列番号2からなる群より選択されるアミノ 酸配列を有する、請求項14の方法。 16.約50までのアミノ酸を有し、かつ以下の配列:配列番号3、配列番号4、 配列番号5、配列番号6、配列番号7、配列番号11、配列番号12、配列番号13、 配列番号14、配列番号15、配列番号16、配列番号17、配列番号18または配列番号 19の1つに含有される活性神経栄養性領域を含むペプチドの有効量を被検者に投 与することを含む、被検者の神経障害痛を軽減する方法。 17.約50までのアミノ酸を有し、かつ以下の配列:配列番号3、配列番号4、 配列番号5、配列番号6、配列番号7、配列番号11、配列番号12、配列番号13、 配列番号14、配列番号15、配列番号16、配列番号17、配列番号18または配列番号 19の1つに含有される活性神経栄養性領域を含むペプチドの神経障害痛の治療の ための使用。 18.約14から約50のアミノ酸を有し、配列番号2に示す配列を含有するペプチ ドの刺激または抑制有効量を含む組成物とニューロン細胞とを接触させる段階を 含む、神経突起の成長を刺激する、神経細胞死を抑制する、有髄化を促進するま たは脱髄を抑制する方法。 19.組成物が配列番号2に示す配列を有するペプチドを含む、請求項18の方法 。 20.ニューロン細胞をin vitroで接触させる、請求項18の方法。 21.ニューロン細胞をin vivoで接触させる、請求項18の方法。 22.神経組織中の神経または脱髄疾患の治療のための、請求項1または請求項 2のペプチドの使用。 23.抑制有効量のプロサポジンの活性断片を含む組成物とニューロン細胞とを 接触させる段階を含む、知覚または運動神経障害を抑制する方法。 24.プロサポジンの活性断片が約14から約50のアミノ酸を有し、かつ配列番号 2に示す配列を含有するペプチドである、請求項23の方法。 25.プロサポジンの活性断片が配列番号2に示す配列を有するペプチドである 、請求項24の方法。 26.ニューロン細胞をin vitroで接触させる、請求項23の方法。 27.ニューロン細胞をin vivoで接触させる、請求項23の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/611,307 | 1996-03-05 | ||
US08/611,307 US6271196B1 (en) | 1996-03-05 | 1996-03-05 | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
PCT/US1997/004143 WO1997032895A1 (en) | 1996-03-05 | 1997-03-05 | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000506853A true JP2000506853A (ja) | 2000-06-06 |
JP2000506853A5 JP2000506853A5 (ja) | 2004-12-02 |
JP4138006B2 JP4138006B2 (ja) | 2008-08-20 |
Family
ID=24448513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53205097A Expired - Fee Related JP4138006B2 (ja) | 1996-03-05 | 1997-03-05 | プロサポジン由来のペプチドを使用する神経障害痛の軽減方法 |
Country Status (16)
Country | Link |
---|---|
US (2) | US6271196B1 (ja) |
EP (1) | EP0929569B1 (ja) |
JP (1) | JP4138006B2 (ja) |
KR (1) | KR100507715B1 (ja) |
AT (1) | ATE340187T1 (ja) |
AU (1) | AU734566B2 (ja) |
CA (1) | CA2248139C (ja) |
CZ (1) | CZ297384B6 (ja) |
DE (1) | DE69736712T2 (ja) |
IL (1) | IL126082A0 (ja) |
NO (1) | NO984093L (ja) |
NZ (1) | NZ331757A (ja) |
PL (1) | PL187917B1 (ja) |
RU (2) | RU2266129C2 (ja) |
SK (1) | SK122898A3 (ja) |
WO (1) | WO1997032895A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524681A (ja) * | 2003-04-28 | 2006-11-02 | チルドレンズ ホスピタル メディカル センター | サポシンc−dops:新規抗腫瘍剤 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571787A (en) * | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
US6849602B1 (en) * | 1996-03-05 | 2005-02-01 | The Regents Of The University Of California | Compositions for alleviating neuropathic pain with prosaposin receptor agonists |
AU4267297A (en) * | 1997-09-11 | 1998-09-22 | Regents Of The University Of California, The | Method of alleviating neuropathic pain |
EP0979238A4 (en) * | 1997-03-05 | 2000-08-23 | Univ California | METHOD FOR HEALING NEUROPATHIC PAIN |
CA2284105A1 (en) * | 1997-03-24 | 1998-10-01 | John S. O'brien | Synthetic saposin c-derived neurotrophic peptides |
JP2001515866A (ja) * | 1997-09-09 | 2001-09-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プロサポシン受容体アゴニストを利用したアポトーシスの阻害 |
US6458357B1 (en) * | 1997-09-09 | 2002-10-01 | Myelos Corporation | Retro-inverso neurotrophic and analgesic peptides |
CN1324367A (zh) * | 1998-08-28 | 2001-11-28 | 迈洛斯公司 | 环状前塞波素衍生肽及其应用 |
US20020028783A1 (en) * | 1999-09-09 | 2002-03-07 | O'brien John S. | Method of stimulating prosaposin receptor activity |
USRE45976E1 (en) * | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
CA2367766A1 (en) * | 1999-03-30 | 2000-10-05 | Myelos Corporation | Retro-inverso prosaposin-derived peptides and use thereof |
US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
US7109168B1 (en) | 2000-06-16 | 2006-09-19 | Myelos Corporation | Retro-inverso peptides derived from leukemia inhibitory factor |
IL147095A0 (en) * | 1999-06-16 | 2002-08-14 | Myelos Corp | Retro-inverso peptides derived from leukemia inhibitory factor |
CA2376394A1 (en) * | 1999-06-16 | 2000-12-21 | David E. Wright | Retro-inverso peptides derived from interleukin-3 |
IL147094A0 (en) * | 1999-06-16 | 2002-08-14 | Myelos Corp | Retro-inverso peptides derived from interleukin-6 |
US7135461B1 (en) | 2000-06-16 | 2006-11-14 | Myelos Corporation | Retro-inverso peptides derived from interleukin-6 |
US20040170955A1 (en) * | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US20050074747A1 (en) * | 2000-09-08 | 2005-04-07 | Wadih Arap | Biopanning and rapid analysis of selective interactive ligands (brasil) |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US20060287240A1 (en) * | 2001-03-09 | 2006-12-21 | O'brien John S | Method of stimulating prosaposin receptor activity |
US20040176290A1 (en) * | 2001-07-18 | 2004-09-09 | Renata Pasqualini | Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
US20040048243A1 (en) * | 2001-09-07 | 2004-03-11 | Wadih Arap | Methods and compositions for in vitro targeting |
US8507445B2 (en) * | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US7671010B2 (en) * | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
AU2003259846A1 (en) * | 2002-08-16 | 2004-03-03 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
US7166691B2 (en) * | 2002-12-20 | 2007-01-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Saposin C and receptors as targets for treatment of benign and malignant disorders |
ES2402096T3 (es) * | 2003-03-26 | 2013-04-26 | Evotec International Gmbh | Uso de proteínas relacionadas con saposina para prevenir y tratar la obesidad, diabetes y/o síndrome metabólico |
EP1613321A2 (en) * | 2003-03-28 | 2006-01-11 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
CN100366286C (zh) * | 2003-04-28 | 2008-02-06 | 常州南云科技有限公司 | Saposin C-DOPS:一种抗癌新药 |
US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
US7964585B2 (en) * | 2006-03-14 | 2011-06-21 | Case Western Reserve University | Composition and method of treating peripheral neuropathy |
MX356129B (es) | 2008-01-22 | 2018-05-16 | Araim Pharmaceuticals Inc | Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos. |
RU2561582C2 (ru) * | 2010-11-19 | 2015-08-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения |
WO2012115185A1 (ja) * | 2011-02-23 | 2012-08-30 | 北海道公立大学法人札幌医科大学 | 疼痛を治療、改善、または予防するための組成物 |
RU2669692C1 (ru) * | 2017-08-14 | 2018-10-15 | Павел Андреевич Канаев | Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью |
AU2018414543A1 (en) * | 2018-03-23 | 2020-11-19 | Bexion Pharmaceuticals Inc. | Saposin C pharmaceutical compositions and methods of treating cancer |
AU2019240773B2 (en) | 2018-03-29 | 2024-05-16 | Lateral IP Pty Ltd | Cyclic peptides and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE108459T1 (de) | 1986-04-22 | 1994-07-15 | Salk Inst For Biological Studi | Antagonisten des fibroblasten-wachstumsfaktors. |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
EP0979238A4 (en) * | 1997-03-05 | 2000-08-23 | Univ California | METHOD FOR HEALING NEUROPATHIC PAIN |
CA2284105A1 (en) * | 1997-03-24 | 1998-10-01 | John S. O'brien | Synthetic saposin c-derived neurotrophic peptides |
-
1996
- 1996-03-05 US US08/611,307 patent/US6271196B1/en not_active Expired - Fee Related
-
1997
- 1997-03-05 SK SK1228-98A patent/SK122898A3/sk unknown
- 1997-03-05 KR KR1019980707151A patent/KR100507715B1/ko not_active IP Right Cessation
- 1997-03-05 NZ NZ331757A patent/NZ331757A/en active IP Right Revival
- 1997-03-05 EP EP97916005A patent/EP0929569B1/en not_active Expired - Lifetime
- 1997-03-05 AT AT97916005T patent/ATE340187T1/de not_active IP Right Cessation
- 1997-03-05 CA CA002248139A patent/CA2248139C/en not_active Expired - Fee Related
- 1997-03-05 RU RU2003131695/14A patent/RU2266129C2/ru not_active IP Right Cessation
- 1997-03-05 PL PL32870197A patent/PL187917B1/pl not_active IP Right Cessation
- 1997-03-05 JP JP53205097A patent/JP4138006B2/ja not_active Expired - Fee Related
- 1997-03-05 CZ CZ0283998A patent/CZ297384B6/cs not_active IP Right Cessation
- 1997-03-05 WO PCT/US1997/004143 patent/WO1997032895A1/en active IP Right Grant
- 1997-03-05 AU AU23286/97A patent/AU734566B2/en not_active Ceased
- 1997-03-05 DE DE69736712T patent/DE69736712T2/de not_active Expired - Fee Related
- 1997-03-05 RU RU98118091/04A patent/RU2223969C2/ru not_active IP Right Cessation
- 1997-03-05 IL IL12608297A patent/IL126082A0/xx unknown
-
1998
- 1998-09-04 NO NO984093A patent/NO984093L/no not_active Application Discontinuation
-
1999
- 1999-01-15 US US09/231,159 patent/US6268347B1/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524681A (ja) * | 2003-04-28 | 2006-11-02 | チルドレンズ ホスピタル メディカル センター | サポシンc−dops:新規抗腫瘍剤 |
JP4762132B2 (ja) * | 2003-04-28 | 2011-08-31 | チルドレンズ ホスピタル メディカル センター | サポシンc−dops:新規抗腫瘍剤 |
Also Published As
Publication number | Publication date |
---|---|
DE69736712D1 (de) | 2006-11-02 |
CZ297384B6 (cs) | 2006-11-15 |
EP0929569B1 (en) | 2006-09-20 |
US6268347B1 (en) | 2001-07-31 |
EP0929569A1 (en) | 1999-07-21 |
SK122898A3 (en) | 2000-02-14 |
PL328701A1 (en) | 1999-02-15 |
WO1997032895A1 (en) | 1997-09-12 |
US6271196B1 (en) | 2001-08-07 |
RU2266129C2 (ru) | 2005-12-20 |
KR19990087686A (ko) | 1999-12-27 |
NO984093D0 (no) | 1998-09-04 |
CA2248139A1 (en) | 1997-09-12 |
IL126082A0 (en) | 1999-05-09 |
DE69736712T2 (de) | 2007-09-13 |
ATE340187T1 (de) | 2006-10-15 |
CA2248139C (en) | 2004-05-18 |
CZ283998A3 (cs) | 1999-05-12 |
AU734566B2 (en) | 2001-06-14 |
NO984093L (no) | 1998-11-04 |
JP4138006B2 (ja) | 2008-08-20 |
RU2003131695A (ru) | 2005-04-10 |
EP0929569A4 (en) | 2000-08-23 |
KR100507715B1 (ko) | 2006-05-26 |
RU2223969C2 (ru) | 2004-02-20 |
PL187917B1 (pl) | 2004-11-30 |
AU2328697A (en) | 1997-09-22 |
NZ331757A (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4138006B2 (ja) | プロサポジン由来のペプチドを使用する神経障害痛の軽減方法 | |
JP4528443B2 (ja) | 環状プロサポシン由来のペプチドおよびその使用 | |
US20050164948A1 (en) | Methods of treatment with prosaposin-derived peptides | |
JPH09503999A (ja) | 治療剤としてのプロサポシンおよびサイトカイン由来ペプチド | |
JP2009102392A (ja) | プロテインキナーゼcのペプチドインヒビター | |
CA2282827A1 (en) | Method of alleviating neuropathic pain | |
WO2020094002A1 (zh) | 抗癫痫的毒素Martentoxin及其应用 | |
CA2300221A1 (en) | Retro-inverso neurotrophic and analgesic peptides | |
AU2002300005B2 (en) | Method of alleviating neuropathic pain | |
JP2001524944A (ja) | 神経障害性疼痛の緩和方法 | |
CA2284105A1 (en) | Synthetic saposin c-derived neurotrophic peptides | |
MXPA98007245A (en) | Methods to alleviate neuropathic pain using peptides derived from prosapos | |
CN1224430A (zh) | 利用prosaposin衍生多肽缓解神经性疼痛的方法 | |
MXPA01001966A (en) | Cyclic prosaposin-derived peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070918 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080507 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080605 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |